Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid ...

I ordered a PetSafe dog harness from online. It took 2 weeks to come and when it finely came I got a filter. IT WAS A FILTER NOT A DOG HARNESS. I called customer service about it, they said they would ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...